0001193125-21-246851.txt : 20210816 0001193125-21-246851.hdr.sgml : 20210816 20210816065205 ACCESSION NUMBER: 0001193125-21-246851 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210813 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareMax, Inc. CENTRAL INDEX KEY: 0001813914 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-NURSING & PERSONAL CARE FACILITIES [8050] IRS NUMBER: 850992224 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39391 FILM NUMBER: 211174420 BUSINESS ADDRESS: STREET 1: 1000 NW 57 COURT, SUITE 400 CITY: MIAMI STATE: FL ZIP: 33126 BUSINESS PHONE: 786-360-4768 MAIL ADDRESS: STREET 1: 1000 NW 57 COURT, SUITE 400 CITY: MIAMI STATE: FL ZIP: 33126 FORMER COMPANY: FORMER CONFORMED NAME: Deerfield Healthcare Technology Acquisitions Corp. DATE OF NAME CHANGE: 20200602 8-K/A 1 d195993d8ka.htm FORM 8-K/A Form 8-K/A
true 0001813914 0001813914 2021-08-13 2021-08-13 0001813914 us-gaap:CommonClassAMember 2021-08-13 2021-08-13 0001813914 us-gaap:WarrantMember 2021-08-13 2021-08-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

(Amendment No. 1)

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2021

 

 

 

LOGO

CareMax, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39391   85-0992224

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1000 NW 57 Court  
Suite 400  
Miami, Florida   33126
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 786 360-4768

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A common stock, par value $0.0001 per share   CMAX   The NASDAQ Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share   CMAXW   The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Explanatory Note

On August 13, 2021, CareMax, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2021. The Company is filing this Amendment No.1 to the Company’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission on August 13, 2021 (the “Original Report”) solely to include the form of press release as was actually disseminated on August 13, 2021 as Exhibit 99.1. Except as expressly set forth herein, this amendment does not amend, modify or update the disclosures contained in the Original Report.

Item 2.02 Results of Operations and Financial Condition.

The information contained in Item 7.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.02.

Item 7.01 Regulation FD Disclosure

On August 13, 2021, the Company issued a press release announcing its financial results for the second quarter ended June 30, 2021 and provided an investor presentation to accompany the press release. The Company also issued a press release announcing a collaboration agreement with Anthem. Copies of the press release announcing its financial results, the investor presentation and press release announcing a collaboration agreement with Anthem are furnished as Exhibits 99.1, 99.2 and 99.3, respectively, to this Current Report on Form 8-K and is incorporated herein by reference.

This information and the information contained in Exhibits 99.1, 99.2 and 99.3 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

    

Exhibit Index

99.1    Press Release issued by CareMax Inc. on August 13, 2021.
99.2    Investor Presentation of CareMax Inc. on August 13, 2021 (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K (File No. 001-39391), filed with the SEC on August 13, 2021).
99.3    Press Release from CareMax, Inc., dated August 13, 2021, entitled “CareMax Signs Collaboration Agreement with Anthem” (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K (File No. 001-39391), filed with the SEC on August 13, 2021).
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      CareMax Inc.
Date: August 16, 2021     By:  

/s/ Carlos de Solo

      Carlos de Solo
      Chief Executive Officer
 EX-99.1 2 d195993dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

CareMax Inc. Announces Second Quarter 2021 Financial Results

Miami, FL – August 13, 2021 – CareMax, Inc. (NASDAQ: CMAX; CMAXW), a leading technology-enabled provider of value-based care to seniors, announced today financial results for the second quarter ended June 30, 2021.

Business Highlights

 

  •  

Announced collaboration with Anthem described in separate press release issued earlier today

 

  •  

Entered into agreement with The Related Companies, a leading national affordable housing developer, to support CareMax in opening centers inside or near affordable senior housing nationwide

 

  •  

Anticipate opening at least 75 new CareMax centers over the next three years

 

  •  

Completed the acquisition of Senior Medical Associates (SMA) and entered into a definitive agreement to acquire DNF Medical Centers, expanding our penetration in Central Florida

 

  •  

Scheduled Investor Day to discuss key growth strategies on September 9, 2021 at 9:30am ET

Second Quarter 2021 Results1

 

  •  

GAAP total revenue was $44.9 million for the second quarter of 2021 and $72.8 million for the first half of the year.

 

  •  

GAAP net loss was $7.4 million for the second quarter of 2021, or $0.26 per diluted share, and $6.0 million, or $0.31 per share, for the first half of the year.

 

  •  

On a pro forma basis, total revenue was $97.8 million for the second quarter of 2021 and $193.2 million for the first half of the year.

 

  •  

Adjusted EBITDA2 was $1.5 million for the second quarter of 2021 and $10.2 million for the first half of 2021. Direct COVID headwinds accounted for an approximately $11 million reduction in adjusted EBITDA.

 

  •  

The Company ended the quarter with approximately 61,500 total members and 21,500 Medicare Advantage members, not including the more than 4,000 members from the planned acquisition of DNF Medical Centers.

 

  •  

As of June 30, 2021, the Company operated 34 medical centers, with two additional centers in progress and slated to open in 2022. Six additional centers are anticipated to be added as part of the planned acquisition of DNF Medical Centers.

 

1 

GAAP presentation is for CareMax Medical Group and includes the financial information and activities for IMC for the period from June 8, 2021 (the closing of the business combination) to (and including) June 30, 2021 (23 days). Pro forma and other non-GAAP information gives effect to the business combination and the acquisition of SMA as if the transactions had occurred in historical periods.

2 

Adjusted EBITDA and pro forma medical expense ratio are non-GAAP financial metrics. A reconciliation of non-GAAP metrics to GAAP financial statements is included in this release.

Management Commentary

Carlos de Solo, Chief Executive Officer, commented, “After the merger with IMC, the recent closing of our acquisition of Senior Medical Associates and the anticipated closing of the DNF acquisition this quarter, CareMax has a strong, sustainable foundation of profitability in South and now Central Florida from which to take our model nationwide. In our current markets, we are focused on organic growth and constantly improving our care model for the benefit of our members.”

“Anchored by our collaborations with Anthem and The Related Companies, we are developing a unique ecosystem whereby the most underserved communities receive access to our care model. We believe we have the ability to deliver consistent, replicable results nationwide, giving us conviction to accelerate our de novo growth with a goal of opening at least 75 new CareMax centers in the next three years. These key agreements provide us with a multi-faceted growth strategy designed to enable us to confidently expand at a rapid pace.”

“To supplement the outstanding talent in CareMax and IMC, we are in the process of building out an executive team that is capable of implementing our ambitious plans. We are making these investments in talent to maximize the opportunities in our base business as well as execute on the growth opportunities ahead of us.”

“While we, like our peers, experienced headwinds in 2021 related to COVID-19, we believe these challenges are unique to the current pandemic and non-recurring in nature. I am proud and pleased to say that our core business remains sound and growing – a testament to our high-caliber medical and support personnel who have worked tirelessly throughout the pandemic to meet our members’ needs.”

Conference Call

Management will host a conference call at 8:30 am ET today to discuss the results and business activities. Interested parties may participate in the call by dialing:

(877) 407-9753 (Domestic) or

(201) 493-6739 (International)

The conference call will also be available on the Company’s website, ir.caremax.com. Following the live call, a replay will be available on the Company’s website.

An investor presentation has also been posted to ir.caremax.com

About CareMax

CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors. CareMax operates medical centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States. Learn more at www.caremax.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and strategy. Words such as “anticipate,” “believe,” “budget,” “contemplate,” “continue,” “could,” “envision,” “estimate,” “expect,” “guidance,” “indicate,” “intend,” “may,” “might,” “plan,” “possibly,” “potential,” “predict,” “probably,” “pro-forma,” “project,” “seek,” “should,” “target,” or “will,” or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important risks and uncertainties that could cause the Company’s actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, the impact of COVID-19 or any variant thereof on the Company’s business and results of operation; the availability of sites for medical facilities and the

costs of opening such medical facilities; changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to the Company’s services; the Company’s ability to continue its growth, including in new markets; changes in laws and regulations applicable to the Company’s business, in particular with respect to Medicare Advantage and Medicaid; the Company’s ability to maintain its relationships with health plans and other key payers; any delay, modification or cancellation of government contracts; the Company’s future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs; the Company or any other party’s ability to fulfill contractual obligations; and the Company’s ability to recruit and retain qualified team members and independent physicians. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s reports filed with the SEC. All information provided in this press release is as of the date hereof, and the Company undertakes no duty to update or revise this information unless required by law, and forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release.

Use of Non-GAAP Financial Information

Certain financial information and data contained this press release is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any periodic filing, information or proxy statement, or prospectus or registration statement to be filed by the Company with the SEC. Some of the financial information and data contained in this press release, such as Adjusted EBITDA and margin thereof and pro forma medical expense ratio have not been prepared in accordance with United States generally accepted accounting principles (“GAAP”). These non-GAAP measures of financial results are not GAAP measures of our financial results or liquidity and should not be considered as an alternative to net income (loss) as a measure of financial results, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company’s management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes.

The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing the Company’s financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. You should review the Company’s audited financial statements, which have been filed by the Company with the SEC.

A reconciliation for Adjusted EBITDA to the most directly comparable GAAP financial measures is included below.

Use of Pro Forma Financial Information and Pro Forma Non-GAAP Financial Information

The unaudited pro forma statements of operations below are provided for informational purposes only and is not necessarily indicative of the operating results or financial position that would have occurred if the acquisitions of IMC, Care Holdings, and SMA had occurred in the stated historical periods, nor is it indicative of the future results or financial position of the combined company. The unaudited pro forma statements of operations do not give effect to the potential impact, of any anticipated synergies, operating efficiencies or cost savings that may result from the acquisitions of IMC, Care Holdings, and SMA, any integration costs or tax deductibility of transaction costs. Pro forma medical expense ratio is calculated from the unaudited pro forma statements of operations.

Additionally, Adjusted EBITDA presented on a pro forma basis gives effect to the acquisitions of IMC, Care Holdings, and SMA as if they had occurred in historical periods, which does not necessarily reflect what the Company’s Adjusted EBITDA would have been had the acquisitions occurred on the dates indicated. A reconciliation of projected 2021 pro forma Adjusted EBITDA to the most directly comparable GAAP financial measure is not included in this press release because, without unreasonable efforts, the Company is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate this non-GAAP financial measure. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results.

CAREMAX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

     (Unaudited)
June 30,
2021		      December 31,
2020		  

ASSETS

      

CURRENT ASSETS

      

Cash

    $ 170,080      $ 4,934  

Restricted cash

      1,956        —    

Accounts receivable, net

      32,031        9,395  

Inventory

      190        15  

Prepaid expenses, net

      3,449        183  

Risk settlements due from providers

      288        80  

Due from related parties

      —          274  
  

 

 

     

 

 

  

Total Current Assets

      207,994        14,881  

Property and equipment, net

      12,728        4,796  

Goodwill

      356,360        10,068  

Intangible assets, net

      50,357        8,575  

Deferred debt issuance costs

      2,195        —    

Other assets

      998        183  
  

 

 

     

 

 

  

Total Assets

    $ 630,632      $ 38,503  
  

 

 

     

 

 

  

LIABILITIES AND STOCKHOLDERS’/MEMBERS’ EQUITY

      

CURRENT LIABILITIES

      

Accounts payable

    $ 2,546      $ 1,044  

Accrued expenses

      10,689        2,572  

Accrued interest payable

      264        149  

Risk settlements due to providers

      178        643  

Current portion of long-term debt

      6,672        1,004  

Due to related parties

      —          39  

Other current liabilities

      5,771        —    
  

 

 

     

 

 

  

Total Current Liabilities

      26,120        5,451  

Derivative warrant liabilities

      27,337        —    

Long-term debt, less current portion

      114,222        26,325  

Other Liabilities

      2,639        —    
  

 

 

     

 

 

  

Total Liabilities

      170,318        31,776  

COMMITMENTS AND CONTINGENCIES (Note 14)

      

STOCKHOLDERS’/MEMBER’S EQUITY

      

Class A common stock ($0.0001 par value; 250,000,000 shares
authorized; 80,632,457 shares issued and outstanding at June 30, 2021)

      8        —    

Additional paid-in-capital

      199,541        —    

Retained earnings

      260,765        —    

Member units (no par value, 200 authorized, issued and outstanding at
December 31, 2020)

      —          223  

Members’ equity

      —          6,504  
  

 

 

     

 

 

  

Total Stockholders’/Members’ Equity

      460,314        6,727  
  

 

 

     

 

 

  

Total Liabilities and Stockholders’/Members’ Equity

    $ 630,632      $ 38,503  
  

 

 

     

 

 

  

CAREMAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)

 

     Three Months
Ended
June 30		     Three Months
Ended
June 30		     Six Months
Ended
June 30		     Six Months
Ended
June 30		  
     2021     2020     2021     2020  

Revenue

         

Medicare risk-based revenue

    $ 37,761     $ 25,746     $ 65,577     $ 50,841  

Medicaid risk-based revenue

      5,449       —         5,449       —    

Other revenue

      1,709       49       1,811       188  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total Revenue

      44,919       25,795       72,837       51,029  

Expenses

         

External provider costs

      35,535       15,958       53,694       31,806  

Cost of care

      7,867       3,886       13,220       7,903  

Sales and marketing

      775       272       1,066       500  

Corporate, general and administrative

      8,881       1,456       10,676       2,740  

Depreciation and amortization

      1,437       356       1,951       712  

Acquisition related costs

      149       —         149       —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Total costs and expenses

      54,644       21,928       80,756       43,661  
  

 

 

    

 

 

    

 

 

    

 

 

  

Operating income (loss)

      (9,725 )      3,867       (7,919 )      7,368  

Interest income (expense), net

      (792 )      (403 )      (1,296 )      (730 ) 

Gain (loss) on remeasurement of warrant liabilities

      1,795       —         1,795       —    

Gain (loss) on extinguishment of debt

      1,358       —         1,358       —    

Other expense/(income)

      —         —         —         —    
  

 

 

    

 

 

    

 

 

    

 

 

  

(Loss) income before income tax

      (7,364 )      3,464       (6,062 )      6,638  

Income tax provision (benefit)

      —         —         —         —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income (loss)

    $ (7,364 )    $ 3,464     $ (6,062 )    $ 6,638  

Net income (loss) attributable to non-controlling interest

      —         82       —         (8 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income (loss) attributable to controlling interest

    $ (7,364 )    $ 3,382     $ (6,062 )    $ 6,646  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income (loss) atrributable to CareMax, Inc. class A common stockholders

    $ (7,364 )    $ 3,382     $ (6,062 )    $ 6,646  

Weighted average basic shares outstanding

      28,404,759       10,796,069       19,649,057       10,796,069  

Weighted average diluted shares outstanding

      28,404,759       10,796,069       19,649,057       10,796,069  

Net income (loss) per share

         

Basic

    $ (0.26 )    $ 0.31     $ (0.31 )    $ 0.62  

Diluted

    $ (0.26 )    $ 0.31     $ (0.31 )    $ 0.62  

CAREMAX, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

 

     Six Months
Ended
June 30,
2021		     Six Months
Ended
June 30,
2020		  

CASH FLOWS FROM OPERATING ACTIVITIES

     

Net (Loss)/Income

    $ (6,062 )    $ 6,638  

Adjustments to reconcile net (loss)/income to net cash

     

Used in operating activities:

     

Depreciation expense

      640       431  

Amortization expense

      1,320       281  

Amortization of discount on debt and related issuance costs

      135       35  

Change in fair value of warrant liabilities

      (1,795 )      —    

Gain on extinguishment of debt

      (1,358 )      —    

Changes in operating assets and liabilities:

     

Accounts receivable

      1,267       (3,607 ) 

Prepaid expenses

      (1,322 )      9  

Risk settlements due from/due to providers

      (208 )      128  

Due from related parties

      235       68  

Other assets

      (275 )      18  

Accounts payable

      (2,113 )      (52 ) 

Accrued expenses

      6,454       (55 ) 

Other liabilities

      (16 )      —    

Accrued interest

      115       —    
  

 

 

    

 

 

  

Net Cash (Used In)/Provided by Operating Activities

      (2,983 )      3,894  

CASH FLOWS FROM INVESTING ACTIVITIES

     

Purchase of property and equipment

      (1,527 )      (1,592 ) 

Acquisition of businesses

      (210,252 )      —    

Purchase of noncontrolling interest ownership

      —         (267 ) 
  

 

 

    

 

 

  

Net Cash Used in Investing Activities

      (211,779 )      (1,859 ) 

CASH FLOWS FROM FINANCING ACTIVITIES

     

Proceeds from issuance of Class A common stock

      410,000    

Issuance costs of Class A common stock

      (12,471 )      —    

Recapitalization transaction

      (108,799 )      —    

Proceeds from borrowings on long-term debt and credit facilities

      125,000       2,500  

Principal payments on long-term debt

      (24,496 )      (30 ) 

Payment of deferred financing costs

      (6,883 )      —    

Long-term debt extinguishment costs

      (487 )      —    

Borrowing under paycheck protection program

      —         2,164  

Distributions to members

      —         (81 ) 
  

 

 

    

 

 

  

Net Cash Provided by Financing Activities

      381,864       4,553  
  

 

 

    

 

 

  

NET INCREASE IN CASH

      167,102       6,588  

Cash - Beginning of Period

      4,934       4,438  
  

 

 

    

 

 

  

CASH - END OF PERIOD

    $ 172,036     $ 11,026  
  

 

 

    

 

 

  

Pro Forma Statements of Operations (Unaudited)1

 

     Three Months Ended June 30,  
$‘000s    2021     2020      $ Change     %
Change		  

Revenue

          

Medicare Risk-Based Revenue

    $ 71,902     $ 67,883      $ 4,019       5.9 % 

Medicaid Risk-Based Revenue

      20,454       14,828        5,626       37.9 % 

Other Revenue

      5,424       4,980        444       8.9 % 
  

 

 

    

 

 

     

 

 

    

 

 

  

Total Revenue

    $ 97,780     $ 87,691      $ 10,089       11.5 % 

Operating Expense

          

External Provider Costs

      73,491       56,027        (17,464 )      31.2 % 

Cost Of Care

      12,762       10,465        (2,297 )      21.9 % 

Sales And Marketing

      1,688       1,245        (444 )      35.6 % 

Corporate, General And Administrative

      20,720       8,407        (12,313 )      146.5 % 

Depreciation and Amortization

      3,780       4,077        297       (7.3 )% 
  

 

 

    

 

 

     

 

 

    

 

 

  

Total Costs and Expenses

    $ 112,441     $ 80,220      $ (32,221 )      40.2 % 
  

 

 

    

 

 

     

 

 

    

 

 

  

Operating (loss) income

    $ (14,661 )    $ 7,471      $ (22,133 )      (296.2 )% 

Interest Expense, Net

      1,666       1,456        (210 )      14.4 % 

Change in Warrant Liability

      (1,795 )      —          1,795    

Loss/(Gain) on Extinguishment of Debt

      (1,358 )      —          1,358    

Other Expense/(Income)

      (29 )      190        218       (115.2 )% 
  

 

 

    

 

 

     

 

 

    

 

 

  

Income/(Loss) Before Income Taxes

    $ (13,145 )    $ 5,826      $ (18,971 )      (325.6 )% 

Provision for Income Taxes

      —         —          —      
  

 

 

    

 

 

     

 

 

    

 

 

  

Net Income/(Loss)

    $ (13,145 )    $ 5,826      $ (18,971 )      (325.6 )% 
  

 

 

    

 

 

     

 

 

    

 

 

  

 

     Six Months Ended June 30,  
$‘000s    2021     2020      $ Change     %
Change		  

Revenue

          

Medicare Risk-Based Revenue

    $ 143,648     $ 137,119      $ 6,529       4.8 % 

Medicaid Risk-Based Revenue

      39,351       25,655        13,696       53.4 % 

Other Revenue

      10,218       10,373        (155 )      (1.5 )% 
  

 

 

    

 

 

     

 

 

    

 

 

  

Total Revenue

    $ 193,217     $ 173,147      $ 20,070       11.6 % 

Operating Expense

          

External Provider Costs

      139,093       112,883        (26,210 )      23.2 % 

Cost Of Care

      25,836       22,841        (2,995 )      13.1 % 

Sales And Marketing

      3,170       2,330        (840 )      36.1 % 

Corporate, General And Administrative

      31,493       16,796        (14,697 )      87.5 % 

Depreciation and Amortization

      7,265       8,424        1,159       (13.8 )% 
  

 

 

    

 

 

     

 

 

    

 

 

  

Total Costs and Expenses

    $ 206,857     $ 163,274      $ (43,584 )      26.7 % 
  

 

 

    

 

 

     

 

 

    

 

 

  

Operating (loss) income

    $ (13,641 )    $ 9,874      $ (23,514 )      (238.2 )% 

Interest Expense, Net

      3,063       2,915        (147 )      5.1 % 

Change in Warrant Liability

      (1,795 )      —          1,795    

Loss/(Gain) on Extinguishment of Debt

      (1,358 )      —          1,358    

Other Expense/(Income)

      385       389        4       (1.1 )% 
  

 

 

    

 

 

     

 

 

    

 

 

  

Income/(Loss) Before Income Taxes

    $ (13,935 )    $ 6,569      $ (20,504 )      (312.1 )% 

Provision for Income Taxes

      —       —          —      
  

 

 

    

 

 

     

 

 

    

 

 

  

Net Income/(Loss)

    $ (13,935 )    $ 6,569      $ (20,504 )      (312.1 )% 
  

 

 

    

 

 

     

 

 

    

 

 

  

 

1 

Figures give effect to the combinations of IMC, Care Holdings, and SMA as if they had occurred in historical periods.

Pro Forma Non-GAAP Financial Summary (Unaudited)1

 

Non-GAAP Financial Summary

             

$‘000s

    1Q20     2Q20     3Q20     4Q20     1Q21     2Q21  

Medicare Risk Revenue

    $ 69,236     $ 67,883     $ 69,104     $ 71,134     $ 71,746     $ 71,902  

Medicaid Risk Revenue

      10,827       14,828       20,565       19,062       18,897       20,454  

Other Revenue

      5,393       4,980       4,032       4,382       4,793       5,424  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total Revenue

    $ 85,456     $ 87,691     $ 93,701     $ 94,578     $ 95,436     $ 97,780  

External Provider Costs

      56,856       56,027       63,719       61,483       65,091       74,491  

Cost of Care

      12,376       10,465       12,222       13,559       13,074       12,762  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Platform Contribution

    $ 16,224     $ 21,199     $ 17,760     $ 19,536     $ 17,271     $ 10,527  

Platform Contribution Margin (%)

      19.0 %      24.2 %      19.0 %      20.7 %      18.1 %      10.8 % 

Sales and Marketing

      1,085       1,245       1,293       1,431       1,482       1,688  

Corporate, General and Administrative

      8,039       5,720       6,182       5,831       7,138       7,293  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA

    $ 7,100     $ 14,234     $ 10,285     $ 12,274     $ 8,651     $ 1,546  

Adjusted EBITDA Margin (%)

      8.3 %      16.2 %      11.0 %      13.0 %      9.1 %      1.6 % 

 

1 

Figures give effect to the combinations of IMC, Care Holdings, and SMA as if they had occurred in historical periods.

Select Pro Forma Non-GAAP Operating Metrics1

 

Pro Forma Non-GAAP Operating Metrics

             
     Mar-20     Jun-20     Sep-20     Dec-20     Mar-21     Jun-21  

Centers

      31       31       32       34       34       34  

Markets

      1       1       1       1       1       1  

Patients (MCREM)2

      28,800       31,500       33,000       32,400       33,100       34,700  

At-Risk

      85.2 %      86.8 %      85.9 %      87.8 %      87.0 %      86.3 % 

Platform Contribution ($, Millions)3

    $ 16.2     $ 21.2     $ 17.8     $ 19.5     $ 17.3     $ 10.5  

 

1 

Figures give effect to the combinations of IMC, Care Holdings, and SMA as if they had occurred in historical periods.

2 

MCREM defined as Medicare Equivalent Members, which assumes the level of support received by a Medicare patient is equivalent to that received by three Medicaid or Commercial patients.

3 

Platform contribution defined as risk-bsaed revenues less external provider costs and cost of care, excluding depreciation and amortization.

Reconciliation to Adjusted EBITDA1

 

Reconciliation to Adjusted EBITDA

             

$‘000s

    1Q20     2Q20     3Q20     4Q20     1Q21     2Q21  

Net Income (Loss)

    $ 3,174     $ 3,464     ($ 357 )    $ 1,293     $ 1,302     ($ 7,364 ) 

GAAP Pro Forma Adjustments

      (2,430 )      2,362       1,139       2,905       (2,091 )      (5,781 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Pro Forma Net Income

    $ 744     $ 5,826     $ 782     $ 4,198     ($ 789 )    ($ 13,145 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Interest Expense

      1,459       1,456       1,442       1,440       1,396       1,666  

Depreciation & Amortization

      4,347       4,077       4,175       4,226       3,485       3,780  

Change in Warrant Liability

      —         —         —         —         —         (1,795 ) 

Loss/(Gain) on Extinguishment of Debt

      —         —         —         —         —         (1,358 ) 

Other Expenses

      199       190       301       (345 )      413       (29 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

EBITDA

    $ 6,749     $ 11,548     $ 6,701     $ 9,520     $ 4,505     ($ 10,881 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Other Adjustments

             

Non-Recurring Expenses

      (306 )      2,008       2,831       1,874       2,979       8,622  

Acquistions Costs

      656       678       789       893       1,168       3,806  

Discontinued Operations

      —          (0 )      (35 )      (12 )      (1 )      (0 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA

    $ 7,100     $ 14,234     $ 10,285     $ 12,274     $ 8,651     $ 1,546  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

 

1 

Figures give effect to the combinations of IMC, Care Holdings, and SMA as if they had occurred in historical periods.

Contacts:

CareMax, Inc.

Media

Christine Bucan

(305) 542-8855

Christine@thinkbsg.com

Investor Relations

Ben Quirk

(415) 640-3715

ben.quirk@caremax.com

The Equity Group Inc.

Devin Sullivan

(212) 836-9608

dsullivan@equityny.com

EX-101.SCH 3 cmax-20210813.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 cmax-20210813_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 cmax-20210813_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Elected Not To Use the Extended Transition Period Amendment Description Amendment Description Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Statement [Table] Statement [Table] Document Information [Line Items] Document Information [Line Items] Class A common stock Class A common stock [Member] Warrants Warrants [Member] EX-101.PRE 6 cmax-20210813_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g195993g0816040806055.jpg GRAPHIC begin 644 g195993g0816040806055.jpg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g195993g16g24.jpg GRAPHIC begin 644 g195993g16g24.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @," M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# __$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+$ " 0,# @0#!04$! 7T! @, M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( #< U ,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /WY9MF/3G].G>C2W:VP=MDNM^BL]?*UD?//Q2_:=^%_PGNV MTG6M4GU37UB+MH?AZ"#4KVS)R(SJ+RWUM:V&>#Y<]S'*P(*(0:^IR/@_.<\7 MM5IES#J%W; M7,O/^H^T>=T^3FOFLZX)SK)(.O5IT\1A8QYG4H3<[*]G>,X4YJSW]RUM4VM3 M[KAKQ2X9XC='"TZU7!YE6FH1HXBE[.+>EO>A4K0]Y?#^\[)I/0^F$9CG( QC M;CC(.<=_;VKY#;Y'Z0E)+WK73=DNVEOU^XDZ?A_2C\!H;NP/I_3VJ4JE_LV^ M8[=!0>!VX!],56WR%:VG8"=O^?3%"7R2_I!HEO9(9OQGMM_#^M"C)=K=-_Q# M1):I)[?UT'!O_K?YS3LUOT[!MU5EV#.W\/2DE\K;#MV=K=QN_P!OY<8_&FHR M5[VLMK7_ !_X 6[25UTN.!Y _P \4K-/I9"NEI?7L.H 9NQZX6M\@SCVQ^%3"I M=M-/3:R"UA0?T_I3C-.32VCY!:WR%''^?2J3T[:O\[(6PA./\^E/;R&E\K"9 M]JFU3^[^(['SU^T[\4KSX3_"Z^UC2"B^(-9NH_#F@R/R+6_O[:YGDU#;GDVM MC:7:4TFM[7::M<_/ M/$SB>?"W"U?%X>4H8O%U:6$H2BM8RJ'-*F%]XHU<7"2:UJ^JZ@S3P6B7%T)#)<78BGDN;IM[QIC85D MD5A^P\6\2QX9RRCALL]G2Q=2%.&'IJDN6E3BXN4Y*5-P?N+E2]Z7-43T:;7\ MY>'?!^(XZSBOC,ZE4Q67T74J8JI5:M"$6IQGI4DI.SC'DA)7:M"7Z:1 M?LJ_ B&T%E_PKC29$6$1FYEO]:>\=@ ID:X.I^;N(&=P<'/0"OQ]\:<3^W^L M?VQ5B^;FY%&G[-/MR.GR\OE8_HV'A9P'3PZPW]@4VHQY?:.=;VFWQ%;N^;PAJUXO]ESRS,VH>'=;M@;J.R>]B094@&6U MF9EDS REG=/Y9TZD90@J=:,DW&4?=C3BXP:BU[GO0 MO=MW?\^>(_ D^"\PCFN2PJ4I#G4DYQ4:B5 MX\LE']//V>?'&J^/?A'X0\2^('>36;FTN;._NG0)]ON=)O[G3'U!!'F,BY%N MDS&/Y-\D@4E5!K\7XFRREDV=8O!49PE0@XN/+)NS=[IM[/167;7J?TKP+F^( MSSAO X[%<[Q,O,/%-M87LRAX M-)M8;O4-7=.TC:=9(\L$). ))A&C9X)I99PUG><1D\NP3JQBU%SE.E3BF]K. MK.'/;JHB=54ZF(Q%"G?^(\-7MV?PWE^'H?2_@[QSX3 M\>:-;:[X1UVRUW3)P%^T6;LQAF4#?;W43HLEI&BF2-QW45\EF&58_**[P MN84'0KP\XRC*UM8R@W"2_P +LMM&K'Z+DV>93Q!A7B\FQBQ>&C;WN6I"44[\ MO-"K&%1/3JOGKKSOQ2^+?@KX1:/9ZUXSO[FTM[^[-AI\%E93WUY>7*Q&>188 M(1C;'"I=FD95 QSD@'HR;(\QSW$2P^6T/;3I1YIISC323=EK.4;ZWT5_0X^( M^*,FX6PM+&9Q7=&G6DX4TJ=2HY-).7NTXRM9-:NVZ.'U_P#:;^#_ (=\*^'/ M%]WXF>XTWQ5#)-HMI86-S,$LI%= MV"X/S[&XS&8&CA6ZN#TJ8^(_".79;@\SK8[FH M8]+V48TJTIZP4]::BI0T?VDNQUGPQ^-/P]^+-O>2^"]<^V3Z<5%]IEW;3Z?J M=FK$!)I+.Y4,ULS$(L\9DC9OE#;N*Y$I6 M;LVD[.R;Z.WJ\/<8,SO%QPU!.,5 MI*K-N5^6U.DIU-;;\MEU:/GE/VVO@5]H\@ZIXACAW8^W-X MT^JXBUKV3Y>3GU[*-_(^D_!_C?PIX[TBWUWPGKNGZ[ITH ,]C-O>WE*@FWO+ M=E2:SNE##=#/%&XR"5 (S\GF&78S*J[PV-PTZ%6+Y?>M9O17C)-J2=UK%R2O MJT?HF49SE/$&$HYCD^+CB<-./.K*4)J+NESTJBC4@]'93BF[:7NCH[S4++3K M::[OKF*TM;:-I9[B=O+AAC0.9&L;)[FPU58FF.FWZ MK'*\:8#M;3)*R3[>I4%7 !8KM&:^AXC)2 ME!IN5K*?-HWRVLWTX7,\+BVX0;A47V&FM.Z:O'RM>^FUC(\8_'#PGX2O)=,4 M76LZA;$K=0:=Y7DVKJ.89KF655-P,KNCC#E(W#V45I8:U3%U*; M491HPUYFVDE*# M-9N8K+4(]0\/S3NL<,M\D;V>]L!5DNK>5O)RQ W2(J#JQ Z\&6>*G#>.KT\+ M7CB,NG5E&%-SINSDVDM:$ZBBDVE>5M^UR:.$VU9.,FOO2LCWI9HG M171PR, RLOS*RGH5(X8$8Z9ZCU%?J%.I"JH.G)2C)7BUM9>>R^9ZL5S?#J&O","W&O:M;V D.(8&$DMU,00N8;2!6ED3/!8)M!(R:\?.N(\HX>I0J MYIBXT(R=E&,9U9[7^"E&;?\ #0?P[#X^ MU:OL!"^;_9$XC.< ,H+[\9_V3]*^0J>*?"=-PO7G:3LI?5JKZ7V2&/%UL]QX?U:&^$.#-#MEANH 2 #- M:SHLD8+$#)7![&OJ\HXDRC/N>.4XR-6I22'? ]I;76NW4T*WDWD6L5O;RW$\SJN^0K&@P$1< M%F) !91R2 8S_B7*N&\/0KYC7^KQKRC&#]E5J7;O:ZI0FX[/XD@K8O#X:*E6 MJ=0ZL5+,I5XW16BE5@0T;*& M4C!'KZ65YGA MJ>J_!V:MVLUMI;R2*!2 ;BX$*GRH^1CJQ M&2JD*V/&SSC'(>'JU+#9CB^2O43Y;)M< M]?&X;#:5:O*[\MN63U[>ZG;8[BUNX+NV@NK>036]S%'/!*O*R0RJ)(W&0."C M*<8&,XKZ/#UZ6*H4,50O*CB*<*M-_#>%2*G%V;3C>+3LTFMFD]#2-:,HQE&5 MXR2:T>SU6C29^?'_ 4*N)8_#/PUME)$,NO:],RCD>=!I]C%"?\ >$=U< >S M-7Z[X548RQF;U?MTJ%%+_#.I+F_](B?@OC_*K_97#M&+:HSQ=>=O5G5_L#V%O;_ GUN]C \^]\;ZDDK#J(K72='B@B8YY"C>PS_P ]3[5Y MGB96G+B%4D_W%/#TN1=FX0O;KNCV_!'#4:/"U2M&*5>K7J*;ZZ5:J5_E%?)/#7A_Q5IESHWB72=.UO2;@I]HT[4[2&[M)-A5HRT4R,-ZN 0P M&X'H>QVPV+QN"K0KY?7G0KQWE";@^VZ\K?<<.,RS+\TI3PN9X*EC\.[6IUX1 ME!6LUOY]?,DLM)LM#TJVTO0;*STRRL(4MK"RMH$M;2T@CRL<$4$<86.%5X " M].O)R5.K6Q.*=?&U76]I;VCD^:3ML[O=V;ZKIT6FN&PF%P6&>&P-"&'C0IU/ M8PBE"G"H"\ MM4;Q)>2WC&WT_2;B*65H]+:W1FDEA"-%%'%%&4D?391DN%P_#;C[ M>2E\%-\U*245&)O[2%W M*:@X./*G9JZ<+7NFM+>^_%CX"_LRZ-X*UZWB'AGP3KL&DWLVD7O_ E5S%?K MJ%O:S2V436FHZO-]M66=$1HVA9F!(7!P:^:R?B3C2MF6'E/VV-P56<%/VF'A MRI.2O:3HI1T=_B_&S/L>*N!_#3!Y-BY0HX3 X^C2JRHSCBJM2HYQ@W'W57J7 M]Y+=;]+;_.7[!WB*\L_BEK^@"1UL-=\)3W,ELKLT(OM&O]-%M-A@/GCM;B[A M#$ [6"X 4 ?8>*.$I_V1@L9##QC6I5N7GBDKPE3:MT]UM1:32M9:(^$\"\QQ M&'XAQF61Q-2KA:N$4G%M\BG"K3UY7HG:O&\)FX8S.*J7,E2PW*NWO5;O7:_Z'T_CY)K \-1FW*,JV M/NH^4<+:Z5MKNWS/$OV9OV:=/^-6C:EXF\9:UK-IX?T>Z_L'0[+29H8II+B, MMJ5\QEOK:Z2*RCGU(,L<48+3R3-G KV^,^+'P_BJ&#RVA"ACZ\95*\^2*]WW M6FWU]Z3[:ZZ['Q_AKP'#B_#8O&9QB*LK:]^T[\>;6V>_G@L-$OK-*ES5 MU1IRFX4TYU,1/EYTIM)M>TO&.J3BHI*UD?SOCL9C?$#CJO@<3CG' U\77C1I MU)2I4J5##N?*K)**Y:=-7>KYKOF;;;_1&^_9&^ =QX8?1+;1_L&IBT$$7B:# M6KUM;2Y50$O)?-NVM93YA!:%K;R]I(55ZC\II<<\7T\9]9G7KRPDJB:PRBN1 M1O91M:Z25VK2E9V;3U1^[U?"[P]_LQ86-+#+$TZ7+'$?6JC*\>*2.0#/DWDT>.FS](XLP='B#A19M/#QCC(858FC.2]G*/LU&I)2Y;)N5. M+BD^9;+L1CI8.M"+]I3J1_>PH>SE*#Y5&HZ;? M*X.T=VFU+[9_:,\674E_IG@ZV9EM8K:+4]1C7A;JXG:9+&W<9Q)%&MN\I5L@ MF1,CY:_@#Q:SS$QS#!<-X2M42JTJ=6M&#LFZDZB]FWI=2C"*LM/>UZG].YWB M97^JTGRVY-M/CY7^%SN_!/P)\*6.BVLWB>P76-7NH8Y[I9YIDM;-I$W?9[6* MWDBQM! 9G+Y.<8%?4\,^&>04\JPDLVP<,PQ=1.JYU'4;BI^]"-U*/P)VV.K" M91A8T8^VM*F7DSI:20S2"ZTK4(XF9 MX4N')?R'@$K1$D\)(ASQ7YUQSPU6X/S*EF>3UIX;!5N547"5V]$[GCYC@ZF72^LX>5J;]U6>J>_7Y&[\&?A/:>)K9O$WBFW>;3)'EB MTNP\^:*/4?+9O/OYWAD1VA$LC(B@KYA#LVX "O3\/>"*6<8>MG'$&%E5HJ;5 M&G5E)R^",IRDHS[\BC=O6+LEUZ\KR^6(MB<2N:&R3[[KMHCHOBS\%M#T[0KK MQ%X2M382Z7#]HO\ 3DFFEMKBSB.ZXGB6XDD>*>*)-Y"N%98B-N>3ZW&GA[@, M)EL\SR6C'#3P4)U=)233@N9-70BH.U>QX2YYB,PRW, M=?$Y97C&,YN_P"[G23LI;NTH2T?<>2XJI4H2A5DW.+5K]K>7FS@=9^% MWC3QG\3=3E\00SP:(UV\BZO%(C1C1XL"QM; [CMG*!%,90['WL037R^.X+XB MX@XJQU?-<.UE<:DE3JO%J*=%5)*G%4HU8M1ZCJOPL^#^F:>]M?VVEZ0[0^3_:=QK$]O?HVQ@)?-EO5#.K;3\RLI M(P5QT^PQ_!_AY@L*H5:6'PLW:G&3K59U?:6T]WVLVM(R;=DEM>[1VRP654Z7 MLJG*IQ2>N]UIW5]^Q\R_"B_ET;XE:)%8W6;:YU&;297@*^3>6<_FQ*S;0!(C M/%%(I.>8P1U-?D' V(EEG%U"CA,9*6#KSG3E%2E9J-2/+H_*Y\[EL:E#,IJ% M5JF]$DW:W-V?D?8GQ3\"1>.?#3V4+)%JVGL;O2+AN +A$;=:RMD8MYU 1R> M51_X,5^_<;<.4^(\GK8:,(_6Z#C4HW?+;DELFMO=;MH?68["QQ="48)7CJOD M?*/PV^(^H?#&[UC1]8M;MM/*W DTUQ^_L-:ACD2(!&91$DKQ*DI&1]UQG'/X MAPOQ=CN#,7F.5YG&K5IQC.,(JTXTJD%'E4=5;FLV[:-N[U/G,OQM7 U:]&JW M[.G=);ZZ-?FROX1\-ZU\7O&]SJ.J22&S\_[=KMXBD0);D[8=+MCGAI(AY4:* M?EB+N>G,9#E>8^('$E7,<1S+ >TJ5:WM964(4Y*,*48J]KS5-J,;*T;MV3%A MJ=7,<:VW>BFYN^BTT6GWV1]\VMM%9VUO:VJ1PVUK#'!!$B@)'#"@CCC48Z*B M@?A7]-8>&'P="CA:5.2I86G"E!6^S3BH1Z]HH^SC"G3C&"BDH)12]%;]#XO_ M &[O"EUK?PJTC7[*%I9/"/B2*\O-H+&'2]3M)M.N+@@=(X[U]-+-T49)P 2/ MU'POQU/"\05,+6GR4L?AZD$^GM*=JD$[;:1G9[='N?C'CAE=?&\*8;&8>FYO M*\93J5.7XHT:D94Y.*Z_O/9)I6=OF>/_ +!?Q+TC3_\ A)/ACJ=XMI?ZAJ+> M)- 6=F2*\=;"VM-7LXI&.U+F)+2UE6'@NIG90=C5[?B=DF)E.AG%&E%TZ;5" MLH)7Y5%QIS44K6O%W-?C=O>^)Z=.7_@'])7F^SOS7A:W?XC\ M]_VT_CG=^&X=+^'/@KQ'>:;K]U-'J/BBZT:ZFMKJRTU86;3],:]@97@DNYF$ MSB-U<16T8;Y)\-^K>'7#=/%XB69YC@HUL/3YE0A5IQG"K446GSTY)QE&[27. MG%ZZ:'X#XP\>U\MI1X?R3,*N&QM2$*M>MAIRI5*4'/F2A6IM3C)QA[RIR3Y9 M;^\SVGX#>,/$-G^S=I'CGQU>WVL7FF^'?$?B$W5[(TNIW>AZ5)J5YIWVJ9SN MENGTZUB =MS-\A)))!^8XBP>!J\32P>4TE"G4J4:7+%*,(U*LE%\L=E&-X[* MRU:6I]SP;FN:4N!:F<9_4E7K82C7Q$75E[6I*G2H\\>9M-N3E&=N9M[:GP1H M7C7XW_M0_$:7PI!X[OO"^G7\=YJ-SI-C?W-CH>BZ%:R)#-&UI8RPRZK=H)XX MP)F+3-(S&2*,K7ZCB+E.,,3/#TE1N^9JG25I/DYK)Q;:2BT[GT)DT71-5U1U9K/1=/DEL;*:[5IP@GN7021CC[4I;< M02(F:8O&87"99@:&$IU:D(>SA&$U[TTM?IX09%@, MNS',LZS.OFSPE"K.,JDZT'3E"G.5D^:'-=I.SO>UK:V/G_\ 8<=(_C?M.U3_ M ,(EKR(IX)87.F-M4$Y) $A[_P 7O7U?B0JU3ABBY2<9+$04E=JS46FK=$GL MEHC\[\#91_UQK)R:4L!/E3ZR5?#:V6E[7UMM<][_ ."A"[=%^%H]-4\4CZXM M-$KY?PNDXU,]Y6X\M+"VMI;WJUMMC[7Z0%Z67\+[6KN^ MYZU^P_ D?P*T^0*-T_B7Q%([8&G7UG&PX*O=6LL$?/& )'3V&,GI7QF$G&EB\)4EI3IUJG5:;=3 M]*S.G+$8#,*5.ZJ3PM6$&G9J^J_4_ CX8>"]+\7_$C0_ WBG5+SPM M%JFI7FDW5_'!')=6&J16MR+.S:&X(0/+J<4%J=V"&DXZ9K^F887 M PQ='#TZ-:%*<8*#C5Y9)*+4E:$:KY5RV3BDK)*W\0Y%E+K<8PRG'8ZMET'B M,5AY5Z4G[2-2G[:,O>@U47-.#3=_>4KRW9^@ _8!\-$D#XD>(UYSC^RM."DA M5VGF7!^54'7C:!_#Q^4+Q(=.GKPYA.9R3M:DI7](I+3;?;R/WB/@W>2IQXNQ M[A+FG&//65KMM-3T:OS-RM+WFW>[U(_!/[.OP0^&/Q>\(V>K_%"]UCQU:WT6 MK>'/"US#:6BS:A:>;+:27LEK!(8YUD4S00R3VYD-N=JN PKKS/B?B#.L@Q52 MADT<'ED::A5J1JIZ3[#]H33YK+QU9:KY3-;WND6 M4D)V95I;":2VGB YRVPQ';S_ *Y?7%?POXJ4*F!XQR_'*DO9U:%&I&22=YT_ M;)1EWM*FM)76J/UG.X.EC(UH+FY80E)=.57L[/1M)+7=66NA]G:%J5MJ^DZ9 MJ=JRM!?65MW9IHN6.GV>F6UO8V-K!:6=I$D%K;P(L<5O$@*I'%&H^10M M;X?#T,%1CA\/%0IJRY(JT4MMEIIZ%Q4:<5"$5"&RC%)1^Y:'GWQ<\0VWAWP+ MKDLH#3ZC9RZ19P'@R3ZC'):[L9X6*.229CV$1KY;CG-,-E7#N:>UG>IBL-6I M4Z=N;5TIQYE%Z*SDKM6>B[(X,SKPHX64):FAX]^S/ILT=KXGU9E9 M8+F?3+%"PV[WM%NI)^3R=OGHI'^T,=J^ \&L-*-#.\P<7'#XN=.E"3^)NC3G M*4OYDVJ\5S7N^5)Z11Y?#BE..(JS6CLHIK;1O1=.GX'G^I^/_''Q)\7Q^']# MU>XT6QO[V:RTZSMKJ:S@6V@\V1KF_N8%\R5GMK=I67<^"VQ1T%?*9GQ1Q-Q9 MG$,ORO-*N5TJM>JJ485'1?(I[= M2Y-4^5ZIWZ7_ "1ZII_[.&A1R+=>(?$>JZK("'F,0@L$8XPVZ1O-F P6)/F M\ Y&*^\PWA;@5/ZQGF;5\=5HQO4KO?_@'S[X!6!/BCX?6UXM!XH\NWRQ8&WBGE2 EFY?,7ED,>I;UK M\BX2YGD(R=L:,=B#JTK?=51RQ( SFOZMS3, M,)E.!Q.8XR?LZ%"-F[7DVVHQC9:N\K*VUC[2=2GAZ4ZLO=@EMMZ:;:GYWZQ- MJ_Q,\7ZUJ>DZ8IN;I;K4!:6P5##I^FP$(\CA-LETT$,2%L[I)'55+$"OY5S" MIB.+\\S#%9?AVW4M.>-Q6)G1I MW@]59):1BD_R9ZW^SWXWL]*O+CP=J4<=LNI3O=:==F)82=0$866QN&P,AU0" M$DG:\1B^\V!]SX6\2T,OQ5;AS'4U2GB'5E1K*G'WYTZE^2I-)2;Y7/X[_!OL M>MDN+ITY?5)05.HTUS**3NG?XE9['V4A!4'D9Y'4'&>,@XP<=L<=.U?T'9QT MTT[>6VVA])S16EK\NGW%/5M,L=9TZ]TK4[:*\T[4+6>ROK.=!)!=6MS&8IX) M4/#1M&S*1[U=&M5PM:EB*-25*I0DI1<=&FMG\C#%8/#X[#U<'BJ,:^&KQ<:E M.:O%K1JZ\FE)=FD?E3\5/V)O'&@ZU M"&">]EBBU%(67]U/]HCG!51L=OFK]MR;Q$RK&8"E@,^AR54HQG5G2E5I2<=I M2LI23E_@:4OM6U/Y@XE\'^(\MS+$9CPD^:BJLZE&-+$1P]>C3J-KV5.\J:4( M*7*_WB;A'5-MI\1]F_;8B0:4K?&/8J>4,7NHN0H^7:-1^T,.G&\7(XZ,*[?K M?AKS>V]G@?:;W^KUK7_P>RY?P/(6!\:/9?4/:9FH)>S26/I6Y?\ ']8O\SL_ MA5^Q;X]\0^(K37?BNL&B: ;N+4=2TZ34HM4\0:]()_.GM;EK6:6.QBG^82SR M7+SG>P$8;YZY,V\1,HR[!5\'D2=6O*#C2G"C[.C1G-/]Y3;49.4;WLX6,):6:27Z MA:GX7TJ_\+7W@_[+%;:'?:'=>'C96\:QQ6^F7-B^G-! B@"-4M'VH%Z;!7XI M1QF+I8RGCO:?OJ=6-9R;;ESPDIWV=VVM;_JS^F,1EN"K9=B,H5"%/"8BA4H* MFDU",9PE!I);64KJ_<_)&\^ /[0_P,\<1^(OA]IFH:T;.:>'2M>T!;;43>Z; M/+@VNKZ1(6E7SHEC\Z.2%H\QJ4-6$HVETFI MQ=[Q:W33T1_*2\/N/N#LYCB.'U*HJ33IUJ-6EK%/6$X5.6*B[:IQ<;2:=D>Y MKX"_:M^/L<.E?$W58?A]X$FV#5-/M8;"QOM16&0.(CI-G//<3[O^GVZBA1EC M;R'^8+\RLSX$X6,D_=O*=1I:ZW49.RV>S^SI9%XL\9 M-X7/\S6497%*,Z<)8:'M%*_,VL+1YI^[[MINUKI6O=<+\$_V?/B[\-?V@]'G MDT61?#^@W>I/=^)5GB.BZGH%W975G$(9R^^6]F\^)S:;#+&\?S@(!(?1XEXL MR//>&O9>WG''2DJKH^SU5647S1[6C-Z-=$FM+'E<%< <5<,\;*LL/3E@**JQ MC7C52C4HNM#D?*DI+FC%-1<%:[5DU8^@/VU?AEXR^(/AOP7=>#]&N==D\-ZK MJCZE86'EO?\ V75;>PACN+6W=U-T(Y;3YTCRP5]P! ./E?#W.\ORG$YA'-*K MPU/'4Z,8RBN;E=*4V]/-5/P/M?&;A;-^(\LR;^R**Q-7+ZN((OA[\'M"\/\ BFT73M9:]U;59[#S4EELXM1O6GM(+EHF M*)=?96B:2,,VQW*$DJ:\GC/-,-FV?8G%X5\U!KDA*UN91D[.S[IH^K\-<@QG M#O"V$P./BH8B4W6E&Z?+*I%.4;K^5Z+\3Z+" 9YZ_IU']37RM]$MK'W<8*/- MU4NGEV/SI_:)_9$UGQ%XHO/B)\+'M5U2_P!0&J:SX?GNX].$;6,T@48 M-R[/( 2VX9KMJ87PUGBGC92HQHMN2I)UVXWVCR.5HI;66B['@1QWC;&DLO3 MKQG""I1JMX3X8)+2HXN3YK;O6_6YZ;^SS^R_XSTWQT?BM\8KLS:]!>-JFE:: M^JIJU_=:O/ R-K'B*]A+(UQ 2##;I-,0Z(S,JPK$/+XHXQRZIEM7(N':/L,% M4C&G.:IJFN2$HS2C>[]YQLV]+-VO=-?1,DHM+W4FM[_6'Q?\!MXT\-;+%-VMZ7(]WI:JR1-.64+/ M9"1W15\R( AF;AX4)Z5_-_'O#-;B#*)SP\(RS'"1O0;:3NI)I*3VOK]Y^UYG MAIUL-+V4>:IRV7>VB:^Y6.;^"UGX[\,6TOAOQ-H5S;Z0I>YTJ]-SI\XM9'S) M<63YUETOJD93J4L2\3A9S_>)2Y7 M3CB')1C*\8^[>UKI:VPRIXFC!4<11<>D7=/3IUT/H$'TZ^_' X^M?J"M=7B MU)*W^6VG7H>PU**=EUV;\O*_8".!VP?Y=*B,8QC))_%IS=5?16] 2#7Y'XB\(<2<2YGE[RNI3_L^-&5.K"=;V:4G4;\_P#@'M?A7PO8>$M T_0;!<06<6'D(_>7%PQ+RW,K#[TLDOS' M\ . *_1\ER3"9%ED(FUSP=;SWUO!>R7NDW&G",WM@S%W2VEM'F#F-5E>(E4D5E M&&QFOP+-.!.)\GS6>99'1E6IQDY4:L:E!5*['W4FUK9'S=;*L5 MA<34G@G>$I.:=TFG)N35K/9['80V/QX\=01Z5JLJ>%](8&'4;I[>WL+FX@9= MK@00R23S%D)!5# A[MV/TT,'XH<0TX8;%XF.5X627M*CGA83D[)+2A3G-NW, M[:1WOJHG3"GG%:4(5*G+&+O?F732VWF<9=_!WQGX8\::0?#L$^J6,5[I]U8: MOB-(;?[++#*POQYP,&PQD9P R-A(]K"$Z M_6U['K/Q[T3QMK]EH>F^';"; M4-'\]Y=5@M&4SO?1F+^SC+"6#?947[2VXG:&*%AD+7Z)XFY9Q%F6!PF%R>G& MO0E4I^VI2J>SC*W->4K*[<79KHV>KG-'%XBG"AATE&ZO9]KG7?"7X<1>!M # M781O$&IJDNJR)LD2V )V:?:NI(\B,+_ !8^ M#^N6_B >(O!6G375OJ%P+JXM; JMSINJK)YPN;6 L"+=Y 9=Z$"*4DD8>O@. M,> LWHYJ\SX9H)4YUX5*<*73?V]%9*WGX_*)>TC7P< MG&K*HKQ5DHQM*]GONDOF^Q]0>&VU[^P-'_MY(5UH:?;#4UBD1T%X(U$^&3Y2 M=^=PR_ QQ4:CQ,*5[IP71 M6OY;I?F)I_9;BUYNWX-AM8<8 'ITK2ZML[KII_G8>MK:W77F?^=P"[1TQ[#@ M#\,U-Y=$DET>_P"%U^(HIQU;^Z]-'^?8"O&,=/?IG\:EP4I7EM'9)M+YVM^I44HIQU:_K3N)L(P,<# MD=.#^)]A6BY8?#'E\UI_P1+W(-1O%]D[_P#I3L 3&/E P". !C."<8[9%*UF MG=Z>?](2YXM--6BK+1725K+1>71V%V]L8 Z=!Z?X4FN;?2VSZKOL"3O9_"N_ M7\]OU%"8(XQCOWX]Z&OA_NE.[:UM&.R'TP&;3Z=,X[D9]/2DM+VBX^KT^5F[ M+Y(5GM?EMM;\+Z"!2,]OR[>PH=[KW4UY?\&P-22M[1MK;3;RV$$>". #GZ' M!' [?A3[6O&WV>GX/H*7-)PYK-1Z]=K=AV/;IQ_GFE[UM[6Z#YI+2UTO0^?/ MBYX-\92I-XD\%Z]K\,L,6[4=!M-6OHHKB.(%C/IL44_RW63S"H ?DH XP_Y9 MQ[D/$>)I5\TR#-<5A:U"G%^QHXNM32=.UY*$I*$KQ>L8IMVLDWH>1F6'Q4E[ M7#3JKD2;49I;=KS7W?<<%\,?CCI!SFVVG%24(>T=E)^\X- M6M[SM9<.#SB=)JCBI25I6YIZOIIIS77GT;/KFWNK>\ABGM)X[B"5!)#/ PDA MEC8 J\S37 MY(GVD=NGKC(QQ_C6D59-7?D[O\-07,OM;"[1C& .,8&./:FGR[="MA"O7IS MPW Z?_JJ8\[OS-Q:VU_R8=4[V:$"GN,XZ X.,=._:KM9);\O?_AB%!J3;E=+ M8< 0,8]?3UI.]TMX]=M.W^1<;VUW7Y=/P #';'?L.<5/+)/?FBGHKVLO^ ^G MF/\ "PW9["IY'_,U_P!OS_1A>2ZVL25J(* "@ H * "@ H * "@ H * "@ H M * "@!A3((SP>,=,#Z@TFM]FNB:3MI;9Z/OKZ$\KVOIV/&?B!\%-"\;3+?VE MQ%X>U=I0UU?P:?\ ;$O8UC9 MQ:"\ME,P8H1.S:.E;GQ%.C*;ERWM>G#$4()V:5]WRJ[[>9CCNVO5TNW\C[4T1@\YB\DC.L!GE\A-TC!4$C[5 &3BOLJ 2:A0 4 % !0 4 % !0 4 ?__9 end XML 9 d195993d8ka_htm.xml IDEA: XBRL DOCUMENT 0001813914 2021-08-13 2021-08-13 0001813914 us-gaap:CommonClassAMember 2021-08-13 2021-08-13 0001813914 us-gaap:WarrantMember 2021-08-13 2021-08-13 true 0001813914 8-K/A 2021-08-13 CareMax, Inc. DE 001-39391 85-0992224 1000 NW 57 Court Suite 400 Miami FL 33126 786 360-4768 false false false false Class A common stock, par value $0.0001 per share CMAX NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share CMAXW NASDAQ true false On August 13, 2021, CareMax, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2021. The Company is filing this Amendment No.1 to the Company’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission on August 13, 2021 (the “Original Report”) solely to include the form of press release as was actually disseminated on August 13, 2021 as Exhibit 99.1. Except as expressly set forth herein, this amendment does not amend, modify or update the disclosures contained in the Original Report. XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 13, 2021
Document Information [Line Items]  
Document Type 8-K/A
Document Period End Date Aug. 13, 2021
Entity Registrant Name CareMax, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39391
Entity Tax Identification Number 85-0992224
Entity Address, Address Line One 1000 NW 57 Court
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33126
City Area Code 786
Local Phone Number 360-4768
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Amendment Description On August 13, 2021, CareMax, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2021. The Company is filing this Amendment No.1 to the Company’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission on August 13, 2021 (the “Original Report”) solely to include the form of press release as was actually disseminated on August 13, 2021 as Exhibit 99.1. Except as expressly set forth herein, this amendment does not amend, modify or update the disclosures contained in the Original Report.
Amendment Flag true
Entity Central Index Key 0001813914
Class A common stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol CMAX
Security Exchange Name NASDAQ
Warrants [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol CMAXW
Security Exchange Name NASDAQ
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 3 96 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d195993d8ka.htm cmax-20210813.xsd cmax-20210813_def.xml cmax-20210813_lab.xml cmax-20210813_pre.xml d195993dex991.htm g195993g16g24.jpg http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d195993d8ka.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "cmax-20210813_def.xml" ] }, "inline": { "local": [ "d195993d8ka.htm" ] }, "labelLink": { "local": [ "cmax-20210813_lab.xml" ] }, "presentationLink": { "local": [ "cmax-20210813_pre.xml" ] }, "schema": { "local": [ "cmax-20210813.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 32, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 2, "nsprefix": "cmax", "nsuri": "http://www.caremax.com/20210813", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d195993d8ka.htm", "contextRef": "duration_2021-08-13_to_2021-08-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d195993d8ka.htm", "contextRef": "duration_2021-08-13_to_2021-08-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period", "terseLabel": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A common stock", "terseLabel": "Class A common stock [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caremax.com//20210813/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001193125-21-246851-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-246851-xbrl.zip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